Medscape InDiscussion: Acute Myeloid Leukemia

Author: Medscape

Join Dr Gail Roboz for Medscape InDiscussion: Acute Myeloid Leukemia, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/964529). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Be a guest on this podcast

Language: en

Genres: Health & Fitness, Medicine, Science

Contact email: Get it

Feed URL: Get it

iTunes ID: Get it

Get all podcast data

Listen Now...

MRD and Relapse in Patients With AML
Wednesday, 17 August, 2022

Drs Gail Roboz and Roland Walter discuss measurable residual disease and relapse in patients with acute myeloid leukemia. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/964539). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Bone Marrow Biopsy https://emedicine.medscape.com/article/197802-workup Stem Cell Transplant https://emedicine.medscape.com/article/208954-overview Donor Lymphocyte Infusions https://pubmed.ncbi.nlm.nih.gov/11941577/ Hypomethylating Agents https://emedicine.medscape.com/article/197802-treatment FLT3, IDH2 https://emedicine.medscape.com/article/197802-workup#c9 Measurable Residual Disease https://decisionpoint.medscape.com/oncology/viewarticle/928279 2021 Update on MRD in Acute Myeloid Leukemia: A Consensus Document From the European LeukemiaNet MRD Working Party https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718623/ Measurable Residual Disease as a Biomarker in Acute Myeloid Leukemia: Theoretical and Practical Considerations https://www.nature.com/articles/s41375-021-01230-4 Core Binding Factor https://www.medscape.com/viewarticle/408452_4 Minimal Residual Disease Eradication With Epigenetic Therapy in Core Binding Factor Acute Myeloid Leukemia https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779853/ Minimal Residual Disease Monitoring by Quantitative RT-PCR in Core Binding Factor AML Allows Risk Stratification and Predicts Relapse: Results of the United Kingdom MRC AML-15 Trial https://ashpublications.org/blood/article/120/14/2826/30510/Minimal-residual-disease-monitoring-by MRD-Directed Risk Stratification Treatment May Improve Outcomes of t(8;21) AML in the First Complete Remission: Results From the AML05 Multicenter Trial https://pubmed.ncbi.nlm.nih.gov/23535063/